Wall Street Funds Back China's WuXi AppTec as Weight Loss Drug Orders Soar The recent surge in WuXi AppTec's stock price has made the Chinese biotech company a hot commodity on Wall Street.
Major investment firms like JPMorgan Chase, UBS Group, and BlackRock have increased their stakes in WuXi AppTec, attracted by its lucrative weight loss drugs business.
WuXi AppTec's GLP 1 programmes have proven to be particularly successful, drawing investors from around the globe.